Abstract
Mcl-1 protein has been a key targeted therapeutic protein in treating acute lymphoblastic leukemia because of itsresistance to other previously known drugs. However, a newly synthesized chemical A-1210477 has proven to possessenough affinity to bind to the Mcl-1 protein and disrupt its normal function. As a result, scientists started to test thepotency of A-1210477 combined with other drugs to treat various cancers. This study will examine the effect ofA-1210477 and Bcl-2 inhibitor navitoclax combined to treat acute lymphoblastic leukemia Bal-KHc cell line both invitro by MTT and Annexin V/PI Facs as well as in vivo by measuring the tumor volume in xenograft.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
